Color Sam Margolin convinced.

The Dahlman Rose analyst has hiked his target price for shares of Delek US Holdings to $30 from $20 after company execs reported strong second-quarter profits and said they expect refining to continue to produce big profits. Margolin now rates Delek at 'outperform' and his target boost is lifting Delek shares (Ticker: DK) more than 8 percent to about $26.

Imperial Capital analyst Anthony Esposito has begun covering shares of behavioral health play Acadia Healthcare with an 'outperform' rating. By our count, that's five analysts and five 'buys' for Acadia, which is up almost 80 percent (Ticker: ACHC) since going public last November.

Analyst Sam Margolin may have jumped ship from Global Hunter Securities to Dahlman Rose, but he hasn't changed his mind on Delek US Holdings. In initiating coverage of a number of independent oil refiners, Margolin rates Brentwood-based Delek a 'buy' and has a $20 price target — the same as when he launched coverage at Global Hunter last fall. Delek shares (Ticker: DK) closed Friday trading at $16.36.